Skip to main content

Table 2 Proportion of patients with no radiographic progression according to mSASSS cut-offs of ≤0, ≤0.5, ≤1.0, and ≤ 2.0

From: Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison

  MEASURE 1 (N = 201); ENRADAS (N = 122)
n (% of N)
No radiographic progression, % of patients
∆ ≤0 ∆ ≤0.5 ∆ ≤1.0 ∆ ≤2.0
Primary analysis set (BL to Days 31–743) M: 168 (84%); E: 69 (57%) M: 60.7%; E: 52.2% M: 68.5%; E: 62.3% M: 78.0%; E: 69.6% M: 82.1%; E: 72.5%
Sensitivity analysis set 1 (BL to Days 640–819) M: 178 (89%); E: 82 (67%) M: 61.2%; E: 56.1% M: 68.0%; E: 63.4% M: 77.5%
E: 72.0%
M: 81.5%; E: 75.6%
Sensitivity analysis set 2 (All patients, time-adjusted)a M: 201 (100%); E: 122 (100%) M: 59.8%; E: 50.1% M: 68.5%; E: 62.4% M: 79.2%; E: 72.1% M: 84.6%; E: 75.4%
  1. BL Baseline, E ENRADAS, M MEASURE 1, mSASSS Modified stoke ankylosing spondylitis spinal score, n Number of patients per cohort in each analysis set, N Total number of patients per cohort
  2. aAll patients with BL (≤ Day 30) and post-BL (> Day 30) radiographs, adjusted for difference in time between BL and post-BL radiographs